Article

Another angiogenic gene linked to amyotrophic lateral sclerosis.

The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology (VIB), KU Leuven, B-3000 Leuven, Belgium.
Trends in Molecular Medicine (Impact Factor: 10.11). 09/2006; 12(8):345-7. DOI: 10.1016/j.molmed.2006.06.008
Source: PubMed

ABSTRACT A new study by Greenway and colleagues links mutations in the angiogenin gene to patients with amyotrophic lateral sclerosis (ALS)--a progressive and fatal motoneuron disease. This is an unexpected finding because angiogenin was originally identified as a molecule involved in the formation of blood vessels (angiogenesis). Angiogenin bears striking similarity to vascular endothelial growth factor (VEGF), which is the prototypic angiogenic factor that has recently emerged as a molecule with important neuroprotective activities. Besides VEGF, angiogenin is the second so-called angiogenic factor implicated in ALS, raising the question of whether additional angiogenic factors might have a role in ALS. Overall, these findings identify angiogenin as a novel candidate gene in the pathogenesis of ALS--a discovery that ultimately might lead to the development of new therapeutic strategies.

0 Bookmarks
 · 
149 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die amyotrophe Lateralsklerose (ALS) ist eine neurodegenerative Erkrankung, die innerhalb von 3–5 Jahren zum Tode führt. Die bisher einzige Substanz mit marginalem therapeutischem Potenzial ist der Glutamatantagonist Riluzol, der jedoch nur zu einer durchschnittlichen Lebensverlängerung von 3–4 Monaten führt. Daher hat die symptomatische Therapie einen hohen Stellenwert. In zahlreichen tierexperimentellen und klinischen Studien werden potenziell neuroprotektive Wirkstoffe für eine kausale Behandlung untersucht. In diesem Übersichtsartikel sollen im Kontext mit den zugrunde liegenden Wirkmechanismen aktuelle klinischen ALS-Studien vorgestellt werden.
    Der Nervenarzt 01/2008; 79(6). · 0.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative stress and angiogenic factors have been placed as the prime focus of scientific investigations after an establishment of link between vascular endothelial growth factor promoter (VEGF), hypoxia, and amyotrophic lateral sclerosis (ALS) pathogenesis. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter and mutant superoxide dismutase 1 (SOD1) which are characterised by atrophy and muscle weakness resulted in phenotype resembling human ALS in mice. This results in lower motor neurodegeneration thus establishing an important link between motor neuron degeneration, vasculature, and angiogenic molecules. In this review, we have presented human, animal, and in vitro studies which suggest that molecules like VEGF have a therapeutic, diagnostic, and prognostic potential in ALS. Involvement of vascular growth factors and hypoxia response elements also highlights the converging role of oxidative stress and neurovascular network for understanding and treatment of various neurodegenerative disorders like ALS.
    Oxidative Medicine and Cellular Longevity 01/2013; 2013:635831.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Motor neuron disorders (MND) form a heterogeneous group of neurodegenerative affections: phenotypic description is based on selective injury to the upper motor neuron or lower motor neuron or both. Phenotypic heterogeneity is also present concerning genetic features: genetic factors involved in MND may be causative or susceptibility factors. Consequences of genetic abnormalities lead to metabolic or functional cellular disturbances that are apparently specific for motor neuron disorder. Genetics greatly contribute to our understanding of the pathophysiological mechanisms of motor neuron degeneration. Genetic studies provide pathological hypotheses considering the function of protein encoded. Moreover, when a gene mutation is identified, animal models can be developed to search for modifications induced by the mutation. We propose to detail causative and susceptibility genetic factors involved in MND and to discuss pathological mechanisms that may explain motor neuron death.
    Revue Neurologique - REV NEUROL. 02/2008; 164(2):115-130.

Full-text

Download
86 Downloads
Available from
Jun 5, 2014